- Home
- ROAD vs AGIO Comparison
ROAD vs AGIO Comparison
Compare ROAD & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROAD
- AGIO
- Stock Information
- Founded
- ROAD 2001
- AGIO 2007
- Country
- ROAD United States
- AGIO United States
- Employees
- ROAD N/A
- AGIO N/A
- Industry
- ROAD Engineering & Construction
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- ROAD Industrials
- AGIO Health Care
- Exchange
- ROAD Nasdaq
- AGIO Nasdaq
- Market Cap
- ROAD 3.1B
- AGIO 2.6B
- IPO Year
- ROAD 2018
- AGIO 2013
- Fundamental
- Price
- ROAD $88.52
- AGIO $53.78
- Analyst Decision
- ROAD Buy
- AGIO Buy
- Analyst Count
- ROAD 4
- AGIO 7
- Target Price
- ROAD $71.50
- AGIO $52.33
- AVG Volume (30 Days)
- ROAD 417.3K
- AGIO 726.1K
- Earning Date
- ROAD 11-27-2024
- AGIO 10-31-2024
- Dividend Yield
- ROAD N/A
- AGIO N/A
- EPS Growth
- ROAD 122.95
- AGIO N/A
- EPS
- ROAD 1.34
- AGIO 11.80
- Revenue
- ROAD $1,760,752,000.00
- AGIO $32,871,000.00
- Revenue This Year
- ROAD $18.96
- AGIO $33.38
- Revenue Next Year
- ROAD $36.02
- AGIO $163.06
- P/E Ratio
- ROAD $66.22
- AGIO $4.56
- Revenue Growth
- ROAD 18.84
- AGIO 36.79
- 52 Week Low
- ROAD $39.79
- AGIO $20.96
- 52 Week High
- ROAD $97.26
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- ROAD 60.60
- AGIO 59.21
- Support Level
- ROAD $78.00
- AGIO $43.25
- Resistance Level
- ROAD $97.26
- AGIO $62.58
- Average True Range (ATR)
- ROAD 3.39
- AGIO 2.73
- MACD
- ROAD 0.16
- AGIO 0.71
- Stochastic Oscillator
- ROAD 54.64
- AGIO 54.47
About ROAD Construction Partners Inc.
Construction Partners Inc operates as an infrastructure and road construction company. It provides construction products and services to the public and private sectors. Its services cover the construction of highways, roads, bridges, airports, and commercial and residential sites. The company provides site development, paving, utility and drainage systems, as well as supplies hot mix asphalt.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.